Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | DAO | P14920 | 1/20 | 0.56 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824291 | 0.90 | SMN1; SMN2 (0.63) | TSHRDAONAPRTTP53SRD5A2 | |
| SCHEMBL5311010 | 0.86 | TSHR (0.56) | TSHRDAONAPRTTP53SRD5A2 | |
| SCHEMBL3507435 | 0.86 | CA12 (0.52) | TSHRDAONAPRTTP53SRD5A2 | |
| SCHEMBL8824303 | 0.86 | CA1 (0.67) | CES2CES1CA1CA2ALOX15 | |
| SCHEMBL20721895 | 0.84 | TSHR (0.59) | TSHRDAONAPRTTP53SRD5A2 | |
| SCHEMBL18896444 | 0.84 | TSHR (0.59) | TSHRDAONAPRTTP53SRD5A2 | |
| SCHEMBL8346953 | 0.83 | SRD5A2 (0.74) | TSHRTP53SRD5A2CES2CES1 | |
| SCHEMBL8350483 | 0.83 | BCL2L1 (0.63) | TSHRTP53SRD5A2CES2CES1 | |
| SCHEMBL28014689 | 0.83 | CYP2C9 (0.64) | TSHRDAONAPRTTP53SRD5A2 | |
| SCHEMBL4595048 | 0.83 | TSHR (0.71) | TSHRTP53SRD5A2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166696-B2 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-01-23 | — | — | US | claimed |
| US-20040265899-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2004-12-30 | — | — | US | claimed |
| US-6787635-B2 | azlactone-functionalized support such as a crosslinked polymer containing an alkenyl azlactone; use making combinatorial libraries | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-07 | — | — | US | claimed |
| EP-1373167-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M Innovative Properties Company (US) | 2004-01-02 | — | — | EP | claimed |
| US-20020173051-A1 | Solid phase synthesis supports and methods | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | claimed |
| WO-2002081078-A2 | SOLID PHASE SYNTHESIS SUPPORTS AND METHODS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-10-17 | — | — | WO | claimed |
| EP-4741410-A1 | SOLUBILIZATION GROUP FOR POORLY WATER-SOLUBLE PROTEINS | Glytech, Inc. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | FLAGSHIP PIONEERING, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | THE JOHNS HOPKINS UNVERSITY | 2025-04-10 | — | — | US | disclosed |
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-03-20 | — | — | US | disclosed |
| WO-2025037249-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2025-02-20 | — | — | WO | disclosed |
| US-20240400684-A1 | ANTIBODY-MEDIATED DELIVERY OF CAS9 TO MAMMALIAN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-12-05 | — | — | US | disclosed |
| US-20240173421-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | SEAGEN INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2002006224-A1 | PYRROLIDINE-2-CARBOXYLIC ACID HYDRAZIDE DERIVATIVES FOR USE AS METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001094946-A2 | MICROARRAYS FOR PERFORMING PROTEOMIC ANALYSES | CHIRON CORPORATION (US) | 2001-12-13 | — | — | WO | disclosed |
| US-6228373-B1 | PEPTIDE DIMER, GLYCINE, CYSTINE OR PROLNE AMINO ACID FOR IMMUNOLOGY | ASTRA AKTIEBOLAG (SE) | 2001-05-08 | — | — | US | disclosed |
| US-5922890-A | TRITYL AMIDE OR ACID LINKERS FOR SOLID PHASE SYNTHESIS | NOVARTIS AG (CH) | 1999-07-13 | — | — | US | disclosed |
| EP-0785945-A1 | NEW PEPTIDES WITH IMMUNOMODULATORY EFFECTS | Astra Aktiebolag (SE) | 1997-07-30 | — | — | EP | disclosed |
| US-5612474-A | ANTIBODIES AND IMMUNOLOGY | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996030397-A1 | NEW PEPTIDES WITH IMMUNOMODULATORY EFFECTS | ASTRA AKTIEBOLAG (SE) | 1996-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090699-A1 | FAP TARGETING CYCLIC PEPTIDES AND CONJUGATES THEREOF | FAP, FIBP, FGF23 | TSHR 1413/4885DAO 2508/4885NAPRT 1182/4885 |
| US-20020173051-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | TSHR 3025/4885DAO 1003/4885NAPRT 2396/4885 |
| US-20040265899-A1 | Solid phase synthesis supports and methods | FES, LSS, CCNK | TSHR 3025/4885DAO 1003/4885NAPRT 2396/4885 |
| US-20250114441-A1 | POLYMERIC VACCINE FOR OPIOID ADDICTION | OPRM1, OPRK1, OPRL1 | TSHR 1132/4885DAO 2504/4885NAPRT 792/4885 |
| US-20240173421-A1 | MODULATION OF ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY | CD47, CD2, SSB | TSHR 1004/4885DAO 3925/4885NAPRT 4430/4885 |
| US-20250122502-A1 | Bifunctional Molecules and Methods of Using Thereof | EFTUD2, DDX21, SNRPE | TSHR 3164/4885DAO 2575/4885NAPRT 2195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.